Top

BMC Neurology

Published in:

01-12-2021 | Alzheimer's Disease | Research

Cell type-specific potential pathogenic genes and functional pathways in Alzheimer’s Disease

Authors: Xiao-Lan Wang, Lianjian Li

Published in: BMC Neurology | Issue 1/2021

Abstract

Background

Alzheimer's disease (AD) is a pervasive age-related and highly heritable neurodegenerative disorder but has no effective therapy. The complex cellular microenvironment in the AD brain impedes our understanding of pathogenesis. Thus, a comprehensive investigation of cell type-specific responses in AD is crucial to provide precise molecular and cellular targets for therapeutic development.

Methods

Here, we integrated analyzed 4,441 differentially expressed genes (DEGs) that were identified from 263,370 single-cells in cortex samples by single-nucleus RNA sequencing (snRNA-seq) between 42 AD-pathology subjects and 39 normal controls within 3 studies. DEGs were analyzed in microglia, astrocytes, oligodendrocytes, excitatory neurons, inhibitory neurons, and endothelial cells, respectively. In each cell type, we identified both common DEGs which were observed in all 3 studies, and overlapping DEGs which have been seen in at least 2 studies. Firstly, we showed the common DEGs expression and explained the biological functions by comparing with existing literature or multil-omics signaling pathways knowledgebase. We then determined the significant modules and hub genes, and explored the biological processes using the overlapping DEGs. Finally, we identified the common and distinct dysregulated pathways using overall DEGs and overlapping DEGs in a cell type-specific manner.

Results

Up-regulated LINGO1 has been seen in both oligodendrocytes and excitatory neurons across 3 studies. Interestingly, genes enriched in the mitochondrial module were up-regulated across all cell types, which indicates mitochondrial dysfunction in the AD brain. The estrogen signaling pathway seems to be the most common pathway that is disrupted in AD.

Conclusion

Together, these analyses provide detailed information of cell type-specific and overall transcriptional changes and pathways underlying the human AD-pathology. These findings may provide important insights for drug development to tackle this disease.

Available only for authorised users

Katzman R, Saitoh T. Advances in Alzheimer's disease. FASEB J. 1991;5:278.CrossRefPubMed

Mattson MP. Pathways towards and away from Alzheimer's disease (vol 430, pg 631, 2004). Nature. 2004;431:107. https://doi.org/10.1038/nature02940.CrossRef

Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1997;41:17. https://doi.org/10.1002/ana.410410106.CrossRefPubMed

Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14:388. https://doi.org/10.1016/S1474-4422(15)70016-5

Zhang XW, Wang RH, Hu D, Sun XY, Fujioka H, Lundberg K, et al. Oligodendroglial glycolytic stress triggers inflammasome activation and neuropathology in Alzheimer's disease. Sci Adv. 2020 6:ARTN eabb8680. https://doi.org/10.1126/sciadv.abb8680

Liddelow SA, Guttenplan KA, Larke LEC, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481. https://doi.org/10.1038/nature21029.CrossRefPubMedPubMedCentral

Parodi-Rullan R, Sone JY, Fossati S. Endothelial Mitochondrial Dysfunction in Cerebral Amyloid Angiopathy and Alzheimer's Disease. J Alzheimers Dis. 2019;72:1019. https://doi.org/10.3233/Jad-190357.CrossRefPubMedPubMedCentral

Sarlus H, Heneka MT. Microglia in Alzheimer's disease. J Clin Investig. 2017;127:3240. https://doi.org/10.1172/JCI90606.CrossRefPubMedPubMedCentral

Ising C, Heneka MT. Functional and structural damage of neurons by innate immune mechanisms during neurodegeneration. Cell Death Disease. 2018;9:Artn 120. https://doi.org/10.1038/S41419-017-0153-X

10.

Laurent C, Dorothee G, Hunot S, Martin E, Monnet Y, Duchamp M, et al. Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. Brain. 2017;140:184. https://doi.org/10.1093/brain/aww270.CrossRefPubMed

11.

Fu WY, Wang XJ, Ip NY. Targeting Neuroinflammation as a Therapeutic Strategy for Alzheimer's Disease: Mechanisms, Drug Candidates, and New Opportunities. ACS Chem Nerosci. 2019;10:872. https://doi.org/10.1021/acschemneuro.8b00402.CrossRef

12.

Nott A, Holtman IR, Coufal NG, Schlachetzki JCM, Yu M, Hu R, et al. Brain cell type-specific enhancer-promoter interactome maps and disease-risk association. Science. 2019;366:1134. https://doi.org/10.1126/science.aay0793.CrossRefPubMedPubMedCentral

13.

Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. Nat Genet. 2019;51:404. https://doi.org/10.1038/s41588-018-0311-9.CrossRefPubMedPubMedCentral

14.

Schwabe T, Srinivasan K, Rhinn H. Shifting paradigms: The central role of microglia in Alzheimer's disease. Neurobiol Disease. 2020;143:Artn 104962. https://doi.org/10.1016/J.Nbd.2020.104962

15.

Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, et al. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci. 2008;28:4283. https://doi.org/10.1523/Jneurosci.4814-07.2008

16.

Cai ZY, Hussain MD, Yan LJ. Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer's disease. Int J Neurosci. 2014;124:307. https://doi.org/10.3109/00207454.2013.833510.CrossRefPubMed

17.

Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer's disease. J Cell Biol. 2018;217:459. https://doi.org/10.1083/jcb.201709069.CrossRefPubMedPubMedCentral

18.

Felsky D, Roostaei T, Nho K, Risacher SL, Bradshaw EM, Petyuk V, et al. Neuropathological correlates and genetic architecture of microglial activation in elderly human brain. Nature Communications. 2019;10:ARTN 409. https://doi.org/10.1038/s41467-018-08279-3

19.

Fakhoury M. Microglia and Astrocytes in Alzheimer's Disease: Implications for Therapy. Curr Neuropharmacol. 2018;16:508. https://doi.org/10.2174/1570159x15666170720095240.CrossRefPubMedPubMedCentral

20.

Arranz AM, De Strooper B. The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications. Lancet Neurol. 2019;18:406. https://doi.org/10.1016/S1474-4422(18)30490-3.CrossRefPubMed

21.

Damisah EC, Hill RA, Rai A, Chen FY, Rothlin CV, Ghosh S, et al. Astrocytes and microglia play orchestrated roles and respect phagocytic territories during neuronal corpse removal in vivo. Sci Adv. 2020;6:ARTN eaba3239. https://doi.org/10.1126/sciadv.aba3239

22.

Karch CM, Goate AM. Alzheimer's Disease Risk Genes and Mechanisms of Disease Pathogenesis. Biol Psychiatry. 2015;77:43. https://doi.org/10.1016/j.biopsych.2014.05.006.CrossRefPubMed

23.

Nasrabady SE, Rizvi B, Goldman JE, Brickman AM. White matter changes in Alzheimer's disease: a focus on myelin and oligodendrocytes. Acta Neuropathol Com. 2018;6:ARTN 22. https://doi.org/10.1186/s40478-018-0515-3

24.

Xu J, Chen SW, Ahmed SH, Chen H, Ku G, Goldberg MP, et al. Amyloid-beta peptides are cytotoxic to oligodendrocytes. J Neurosci. 2001;21. https://doi.org/10.1523/Jneurosci.21-01-J0001.2001

25.

Ghiso J, Fossati S, Rostagno A. Amyloidosis Associated with Cerebral Amyloid Angiopathy: Cell Signaling Pathways Elicited in Cerebral Endothelial Cells. J Alzheimers Dis. 2014;42:S167. https://doi.org/10.3233/Jad-140027.CrossRefPubMedPubMedCentral

26.

Keable A, Fenna K, Yuen HM, Johnston DA, Smyth NR, Smith C, et al. Deposition of amyloid beta in the walls of human leptomeningeal arteries in relation to perivascular drainage pathways in cerebral amyloid angiopathy. BBA-Mol Basis Dis. 2016;1862:1037. https://doi.org/10.1016/j.bbadis.2015.08.024.CrossRef

27.

Grubman A, Chew G, Ouyang JF, Sun GZ, Choo XY, McLean C, et al. A single-cell atlas of entorhinal cortex from individuals with Alzheimer's disease reveals cell-type-specific gene expression regulation. Nat Neurosci. 2019;22:2087. https://doi.org/10.1038/s41593-019-0539-4.CrossRefPubMed

28.

Lau SF, Cao H, Fu AKY, Ip NY. Single-nucleus transcriptome analysis reveals dysregulation of angiogenic endothelial cells and neuroprotective glia in Alzheimer's disease. P Natl Acad Sci USA. 2020;117:25800. https://doi.org/10.1073/pnas.2008762117.CrossRef

29.

Mathys H, Davila-Velderrain J, Peng ZY, Gao F, Mohammadi S, Young JZ, et al. Single-cell transcriptomic analysis of Alzheimer's disease. Nature. 2019;570:332. https://doi.org/10.1038/s41586-019-1195-2.CrossRefPubMedPubMedCentral

30.

Lake BB, Chen S, Sos BC, Fan J, Kaeser GE, Yung YC, et al. Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. Nat Biotechnol. 2018;36:70. https://doi.org/10.1038/nbt.4038nbt.4038.CrossRefPubMed

31.

He Z, Han D, Efimova O, Guijarro P, Yu Q, Oleksiak A, et al. Comprehensive transcriptome analysis of neocortical layers in humans, chimpanzees and macaques. Nat Neurosci. 2017;20:886. https://doi.org/10.1038/nn.4548nn.4548.CrossRefPubMed

32.

McKenzie AT, Wang M, Hauberg ME, Fullard JF, Kozlenkov A, Keenan A, et al. Brain Cell Type Specific Gene Expression and Co-expression Network Architectures. Sci Rep. 2018;8:8868. https://doi.org/10.1038/s41598-018-27293-510.1038/s41598-018-27293-5.CrossRefPubMedPubMedCentral

33.

Xia JG, Benner MJ, Hancock REW. NetworkAnalyst - integrative approaches for protein-protein interaction network analysis and visual exploration. Nucleic Acids Res. 2014;42:W167. https://doi.org/10.1093/nar/gku443.CrossRefPubMedPubMedCentral

34.

Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics. 2003;4:Artn 2. https://doi.org/10.1186/1471-2105-4-2

35.

Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. Bmc Syst Biol. 2014;8:Artn S11. https://doi.org/10.1186/1752-0509-8-S4-S11

36.

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498. https://doi.org/10.1101/gr.1239303.CrossRefPubMedPubMedCentral

37.

Becnel LB, Ochsner SA, Darlington YF, McOwiti A, Kankanamge WH, Dehart M, et al. Discovering relationships between nuclear receptor signaling pathways, genes, and tissues in Transcriptomine. Science Signaling. 2017;10:ARTN eaah6275. https://doi.org/10.1126/scisignal.aah6275

38.

Ochsner SA, Abraham D, Martin K, Ding W, McOwiti A, Kankanamge W, et al. The Signaling Pathways Project, an integrated 'omics knowledgebase for mammalian cellular signaling pathways. Sci Data. 2019; 6:Artn 252. doi: https://doi.org/10.1038/S41597-019-0193-4

39.

Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44. https://doi.org/10.1038/nprot.2008.211.CrossRef

40.

Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012;40:D109. https://doi.org/10.1093/nar/gkr988.CrossRefPubMed

41.

Igarashi Y, Nakatsu N, Yamashita T, Ono A, Ohno Y, Urushidani T, et al. Open TG-GATEs: a large-scale toxicogenomics database. Nucleic Acids Res. 2015;43:D921. https://doi.org/10.1093/nar/gku955.CrossRefPubMed

42.

Realegeno S, Kelly-Scumpia KM, Dang AT, Lu J, Teles R, Liu PT, et al. S100A12 Is Part of the Antimicrobial Network against Mycobacterium leprae in Human Macrophages. Plos Pathog. 2016;12:ARTN e1005705. https://doi.org/10.1371/journal.ppat.1005705

43.

Lorenzetto E, Moratti E, Vezzalini M, Harroch S, Sorio C, Buffelli M. Distribution of different isoforms of receptor protein tyrosine phosphatase gamma (Ptprg-RPTP gamma) in adult mouse brain: upregulation during neuroinflammation. Brain Struct Funct. 2014;219:875. https://doi.org/10.1007/s00429-013-0541-7.CrossRefPubMed

44.

Herold C, Hooli BV, Mullin K, Liu T, Roehr JT, Mattheisen M, et al. Family-based association analyses of imputed genotypes reveal genome-wide significant association of Alzheimer's disease with OSBPL6, PTPRG, and PDCL3. Mol Psychiatry. 2016;21:1608. https://doi.org/10.1038/mp.2015.218.CrossRefPubMedPubMedCentral

45.

Rangaraju S, Dammer EB, Raza SA, Rathakrishnan P, Xiao HL, Gao TW, et al. Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer's disease. Mol Neurodegener. 2018;13:ARTN 24. https://doi.org/10.1186/s13024-018-0254-8

46.

Naciff JM, Khambatta ZS, Reichling TD, Carr GJ, Tiesman JP, Singleton DW, et al. The genomic response of Ishikawa cells to bisphenol A exposure is dose- and time-dependent. Toxicology. 2010;270:137. https://doi.org/10.1016/j.tox.2010.02.008.CrossRefPubMed

47.

Gonit M, Zhang JA, Salazar MD, Cui HJ, Shatnawi A, Trumbly R, et al. Hormone Depletion-Insensitivity of Prostate Cancer Cells Is Supported by the AR Without Binding to Classical Response Elements. Mol Endocrinol. 2011;25:621. https://doi.org/10.1210/me.2010-0409.CrossRefPubMedPubMedCentral

48.

Zhou Q, Zhao F, Lv ZP, Zheng CG, Zheng WD, Sun L, et al. Association between APOC1 Polymorphism and Alzheimer's Disease: A Case-Control Study and Meta-Analysis. PLoS One. 2014; 9:ARTN e87017. doi: https://doi.org/10.1371/journal.pone.0087017

49.

Zhou XP, Chen Y, Mok KY, Kwok TCY, Mok VCT, Guo QH, et al. Non-coding variability at the APOE locus Communications. 2019; 10:Artn 3310. doi: 10.38/S41467-019-10945-Z

50.

Johnson ECB, Dammer EB, Duong DM, Ping LY, Zhou MT, Yin LM, et al. Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat Med. 2020;26:769. https://doi.org/10.1038/s41591-020-0815-6.CrossRefPubMedPubMedCentral

51.

Tramutola A, Di Domenico F, Barone E, Perluigi M, Butterfield DA. It Is All about (U)biquitin: Role of Altered Ubiquitin-Proteasome System and UCHL1 in Alzheimer Disease. Oxid Med Cell Longev. 2016;2016:Artn 2756068. https://doi.org/10.1155/2016/2756068

52.

Hegde AN, Smith SG, Duke LM, Pourquoi A, Vaz S. Perturbations of Ubiquitin-Proteasome-Mediated Proteolysis in Aging and Alzheimer's Disease. Front Aging Neurosci. 2019; 11:Artn 324. https://doi.org/10.3389/Fnagi.2019.00324

53.

An H, Harper JW. Ribosome Abundance Control Via the Ubiquitin-Proteasome System and Autophagy. J Mol Biol. 2020;432:170. https://doi.org/10.1016/j.jmb.2019.06.001.CrossRefPubMed

54.

Sung MK, Porras-Yakushi TR, Reitsma JM, Huber FM, Sweredoski MJ, Hoelz A, et al. A conserved quality-control pathway that mediates degradation of unassembled ribosomal proteins. Elife. 2016; 5:ARTN e19105. https://doi.org/10.7554/eLife.19105

55.

Nelson PT, Katsumata Y, Nho K, Artiushin SC, Jicha GA, Wang WX, et al. Genomics and CSF analyses implicate thyroid hormone in hippocampal sclerosis of aging. Acta Neuropathol. 2016;132:841. https://doi.org/10.1007/s00401-016-1641-2.CrossRefPubMedPubMedCentral

56.

McAninch EA, Rajan KB, Evans DA, Jo S, Chaker L, Peeters RP, et al. A Common DIO2 Polymorphism and Alzheimer Disease Dementia in African and European Americans. J Clin Endocrinol Metab. 2018;103:1818. https://doi.org/10.1210/jc.2017-01196.CrossRefPubMedPubMedCentral

57.

Hoekstra MMB, Emmenegger Y, Hubbard J, Franken P. Cold-inducible RNA-binding protein (CIRBP) adjusts clock-gene expression and REM-sleep recovery following sleep deprivation. Elife. 2019;8:ARTN e43400. https://doi.org/10.7554/eLife.43400

58.

Eisele SC, Gill CM, Shankar GM, Brastianos PK. PLEKHA5: A Key to Unlock the Blood-Brain Barrier? Clin Cancer Res. 2015;21:1978. https://doi.org/10.1158/1078-0432.CCR-14-2604.CrossRefPubMed

59.

Cui P, Su JC, Li QM, Xu GM, Zhu NX. LncRNA RHPN1-AS1 Targeting miR-625/REG3A Promotes Cell Proliferation And Invasion Of Glioma Cells. Oncotargets Ther. 2019;12:7911. https://doi.org/10.2147/Ott.S209563.CrossRef

60.

Yu L, Petyuk VA, Gaiteri C, Mostafavi S, Young-Pearse T, Shah RC, et al. Targeted brain proteomics uncover multiple pathways to Alzheimer's dementia. Ann Neurol. 2018;84:78. https://doi.org/10.1002/ana.25266.CrossRefPubMedPubMedCentral

61.

Pereira AC, Gray JD, Kogan JF, Davidson RL, Rubin TG, Okamoto M, et al. Age and Alzheimer's disease gene expression profiles reversed by the glutamate modulator riluzole. Mol Psychiatry. 2017;22:296. https://doi.org/10.1038/mp.2016.33.CrossRefPubMed

62.

Bossers K, Wirz KTS, Meerhoff GF, Essing AHW, van Dongen JW, Houba P, et al. Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease. Brain. 2010;133:3699. https://doi.org/10.1093/brain/awq258.CrossRefPubMed

63.

Manavalan A, Mishra M, Feng L, Sze SK, Akatsu H, Heese K. Brain site-specific proteome changes in aging-related dementia. Experimental Mol Med. 2013;45:ARTN e39. https://doi.org/10.1038/emm.2013.76

64.

Kim JH, Franck J, Kang T, Heinsen H, Ravid R, Ferrer I, et al. Proteome-wide characterization of signalling interactions in the hippocampal CA4/DG subfield of patients with Alzheimer's disease. Scientific Reports. 2015;5:Artn 11138. https://doi.org/10.1038/Srep11138

65.

Silva ART, Grinberg LT, Farfel JM, Diniz BS, Lima LA, Silva PJS, et al. Transcriptional Alterations Related to Neuropathology and Clinical Manifestation of Alzheimer's Disease. PLoS One. 2012;7:ARTN e48751. https://doi.org/10.1371/journal.pone.0048751

66.

Shigemizu D, Akiyama S, Asanomi Y, Boroevich KA, Sharma A, Tsunoda T, et al. Risk prediction models for dementia constructed by supervised principal component analysis using miRNA expression data. Communications Biology. 2019;2:ARTN 77. https://doi.org/10.1038/s42003-019-0324-7

67.

Kuhn A, Kumar A, Beilina A, Dillman A, Cookson MR, Singleton AB. Cell population-specific expression analysis of human cerebellum. BMC Genomics. 2012;13:Artn 610. https://doi.org/10.1186/1471-2164-13-610

68.

Fischer FU, Wolf D, Scheurich A, Fellgiebel A, Neuroimaging AD. Altered whole-brain white matter networks in preclinical Alzheimer's disease. Neuroimage-Clin. 2015;8:660. https://doi.org/10.1016/j.nicl.2015.06.007.CrossRefPubMedPubMedCentral

69.

Ettle B, Schlachetzki JCM, Winkler J. Oligodendroglia and Myelin in Neurodegenerative Diseases: More Than Just Bystanders? Mol Neurobiol. 2016;53:3046. https://doi.org/10.1007/s12035-015-9205-3.CrossRefPubMed

70.

Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA, et al. Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer's Disease. Cell. 2013;153:707. https://doi.org/10.1016/j.cell.2013.03.030.CrossRefPubMedPubMedCentral

71.

Patel H, Hodges AK, Curtis C, Lee SH, Troakes C, Dobson RJB, et al. Transcriptomic analysis of probable asymptomatic and symptomatic alzheimer brains. Brain Behav Immun. 2019;80:644. https://doi.org/10.1016/j.bbi.2019.05.009.CrossRefPubMed

72.

McKenzie AT, Moyon S, Wang MH, Katsyv I, Song WM, Zhou XX, et al. Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimer's disease. Mol Neurodegener. 2017;12:ARTN 82. https://doi.org/10.1186/s13024-017-0219-3

73.

Stygelbout V, Leroy K, Pouillon V, Ando K, D'Amico E, Jia YH, et al. Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology. Brain. 2014;137:537. https://doi.org/10.1093/brain/awt344.CrossRefPubMed

74.

Esposito M, Sherr GL. Epigenetic Modifications in Alzheimer's Neuropathology and Therapeutics. Front Neurosci-Switz. 2019;13:Artn 476. https://doi.org/10.3389/Fnins.2019.00476

75.

Bassani S, Cingolani LA, Valnegri P, Folci A, Zapata J, Gianfelice A, et al. The X-Linked Intellectual Disability Protein TSPAN7 Regulates Excitatory Synapse Development and AMPAR Trafficking. Neuron. 2012;73:1143. https://doi.org/10.1016/j.neuron.2012.01.021.CrossRefPubMedPubMedCentral

76.

Ohrfelt A, Brinkmalm A, Dumurgier J, Zetterberg H, Bouaziz-Amar E, Hugon J, et al. A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimer's Disease. Neuroscience. 2019;420:136. https://doi.org/10.1016/j.neuroscience.2018.11.038.CrossRefPubMed

77.

Maesako M, Zoltowska KM, Berezovska O. Synapsin 1 promotes A beta generation via BACE1 modulation. PLoS One. 2019;14:ARTN e0226368. https://doi.org/10.1371/journal.pone.0226368

78.

Blennow K, Bogdanovic N, Alafuzoff I, Ekman R, Davidsson P. Synaptic pathology in Alzheimer's disease: Relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural Transmission. 1996;103:603. https://doi.org/10.1007/Bf01273157

79.

Plagman A, Hoscheidt S, McLimans KE, Klinedinst B, Pappas C, Anantharam V, et al. Cholecystokinin and Alzheimer's disease: a biomarker of metabolic function, neural integrity, and cognitive performance. Neurobiol Aging. 2019;76:201. https://doi.org/10.1016/j.neurobiolaging.2019.01.002.CrossRefPubMedPubMedCentral

80.

Tan MGK, Lee C, Lee JH, Francis PT, Williams RJ, Ramirez MJ, et al. Decreased rabphilin 3A immunoreactivity in Alzheimer's disease is associated with A beta burden. Neurochem Int. 2014;64:29. https://doi.org/10.1016/j.neuint.2013.10.013.CrossRefPubMed

81.

Solarski M, Wang HS, Wille H, Schmitt-Ulms G. Somatostatin in Alzheimer's disease: A new Role for an Old Player. Prion. 2018;12:1. https://doi.org/10.1080/19336896.2017.1405207.CrossRefPubMedPubMedCentral

82.

Zhao Z, Nelson AR, Betsholtz C, Zlokovic BV. Establishment and Dysfunction of the Blood-Brain Barrier. Cell. 2015;163:1064. https://doi.org/10.1016/j.cell.2015.10.067.CrossRefPubMedPubMedCentral

83.

Winkler EA, Nishida Y, Sagare AP, Rege SV, Bell RD, Perlmutter D, et al. GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration. Nat Neurosci. 2015;18:521. https://doi.org/10.1038/nn.3966.CrossRefPubMedPubMedCentral

84.

Meier S, Bell M, Lyons DN, Ingram A, Chen J, Gensel JC, et al. Identification of Novel Tau Interactions with Endoplasmic Reticulum Proteins in Alzheimer's Disease Brain. J Alzheimers Dis. 2015;48:687. https://doi.org/10.3233/Jad-150298.CrossRefPubMedPubMedCentral

85.

Oikari LE, Pandit R, Stewart R, Cuni-Lopez C, Quek H, Sutharsan R, et al. Altered Brain Endothelial Cell Phenotype from a Familial Alzheimer Mutation and Its Potential Implications for Amyloid Clearance and Drug Delivery. Stem Cell Rep. 2020;14:924. https://doi.org/10.1016/j.stemcr.2020.03.011.CrossRef

86.

Zheng QY, Huang T, Zhang LS, Zhou Y, Luo H, Xu HX, et al. Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases. Front Aging Neurosci. 2016;8:Artn 303. https://doi.org/10.3389/Fnagi.2016.00303

87.

Ma PZ, Li YL, Zhang W, Fang FQ, Sun J, Liu MZ, et al. Long Non-coding RNA MALAT1 Inhibits Neuron Apoptosis and Neuroinflammation While Stimulates Neurite Outgrowth and Its Correlation With MiR-125b Mediates PTGS2, CDK5 and FOXQ1 in Alzheimer's Disease. Curr Alzheimer Res. 2019;16:596. https://doi.org/10.2174/1567205016666190725130134.CrossRefPubMed

88.

Fernandez-Enright F, Andrews JL. Lingo-1: a novel target in therapy for Alzheimer's disease? Neural Regeneration Research. (2016) 11:88. https://doi.org/10.4103/1673-5374.175048

89.

Wang WZ, Zhao FP, Ma XP, Perry G, Zhu XW. Mitochondria dysfunction in the pathogenesis of Alzheimer's disease: recent advances. Mol Neurodegener. 2020;15:Artn 30. https://doi.org/10.1186/S13024-020-00376-6

90.

Wang H, Dey KK, Chen PC, Li YX, Niu MM, Cho JH, et al. Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer's disease. Mol Neurodegener. 2020;15:Artn 43. https://doi.org/10.1186/S13024-020-00384-6.

91.

Swerdlow RH. Mitochondria and Mitochondrial Cascades in Alzheimer's Disease. J Alzheimers Dis. 2018;62:1403. https://doi.org/10.3233/Jad-170585.CrossRefPubMedPubMedCentral

92.

Gollihue JL, Norris CM. Astrocyte mitochondria: Central players and potential therapeutic targets for neurodegenerative diseases and injury. Ageing Res Rev. 2020;59:Artn 101039. https://doi.org/10.1016/J.Arr.2020.101039

93.

O'Neill LAJ, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol. 2016;16:553. https://doi.org/10.1038/nri.2016.70.CrossRefPubMedPubMedCentral

94.

Afridi R, Lee WH, Suk K. Microglia Gone Awry: Linking Immunometabolism to Neurodegeneration. Front Cell Neurosci 2020;14:Artn 246. https://doi.org/10.3389/Fncel.2020.00246

95.

Frisard M, Ravussin E. Energy metabolism and oxidative stress - Impact on the metabolic syndrome and the aging process. Endocrine. 2006; 29:27. doi: Doi 10.1385/Endo:29:1:27

96.

Buck MD, O'Sullivan D, Geltink RIK, Curtis JD, Chang CH, Sanin DE, et al. Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming. Cell. 2016;166:63. https://doi.org/10.1016/j.cell.2016.05.035.CrossRefPubMedPubMedCentral

97.

Lee JK, Kim NJ. Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer's Disease. Molecules. 2017;22:Artn 1287. https://doi.org/10.3390/Molecules22081287

98.

Munoz L, Ammit AJ. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology. 2010;58:561. https://doi.org/10.1016/j.neuropharm.2009.11.010.CrossRefPubMed

99.

Uddin MS, Rahman MM, Jakaria M, Rahman MS, Hossain MS, Islam A, et al. Estrogen Signaling in Alzheimer's Disease: Molecular Insights and Therapeutic Targets for Alzheimer's Dementia. Mol Neurobiol. 2020;57:2654. https://doi.org/10.1007/s12035-020-01911-8.CrossRefPubMed

100.

Konishi H, Okamoto T, Hara Y, Komine O, Tamada H, Maeda M, et al. Astrocytic phagocytosis is a compensatory mechanism for microglial dysfunction. Embo J. (2020) 39. doi:

101.

Ding QX, Markesbery WR, Chen QH, Li F, Keller JN. Ribosome dysfunction is an early event in Alzheimer's disease. J Neurosci. 2005;25:9171. https://doi.org/10.1523/Jneurosci.3040-05.2005.CrossRefPubMedPubMedCentral

102.

Gabbouj S, Ryhanen S, Marttinen M, Wittrahm R, Takalo M, Kemppainen S, et al. Altered Insulin Signaling in Alzheimer's Disease Brain - Special Emphasis on PI3K-Akt Pathway. Front Neurosci-Switz. (2019) 13. doi: Artn 62910.3389/Fnins.2019.00629

103.

Cianciulli A, Porro C, Calvello R, Trotta T, Lofrumento DD, Panaro MA. Microglia Mediated Neuroinflammation: Focus on PI3K Modulation. Biomolecules. (2020) 10. doi: Artn 13710.3390/Biom10010137

104.

Attems J, Yamaguchi H, Saido TC, Thal DR. Capillary CAA and perivascular A beta-deposition: Two distinct features of Alzheimer's disease pathology. J Neurol Sci. 2010;299:155. https://doi.org/10.1016/j.jns.2010.08.030.CrossRefPubMed

105.

Snyder HM, Corriveau RA, Craft S, Faber JE, Greenberg SM, Knopman D, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimers Dement. 2015;11:710. https://doi.org/10.1016/j.jalz.2014.10.008.CrossRefPubMed

106.

Lam D, Enright HA, Cadena J, Peters SKG, Sales AP, Osburn JJ, et al. Tissue-specific extracellular matrix accelerates the formation of neural networks and communities in a neuron-glia co-culture on a multi-electrode array. Scientific Reports. 2019;9:Artn 4159. https://doi.org/10.1038/S41598-019-40128-1

107.

Hillen AEJ, Burbach JPH, Hol EM. Cell adhesion and matricellular support by astrocytes of the tripartite synapse. Prog Neurobiol. 2018;165:66. https://doi.org/10.1016/j.pneurobio.2018.02.002.CrossRefPubMed

108.

Zhao LQ, Woody SK, Chhibber A. Estrogen receptor beta in Alzheimer's disease: From mechanisms to therapeutics. Ageing Res Rev. 2015;24:178. https://doi.org/10.1016/j.arr.2015.08.001.CrossRefPubMedPubMedCentral

109.

Nasrabady SE, Rizvi B, Goldman JE, Brickman AM. White matter changes in Alzheimer's disease: a focus on myelin and oligodendrocytes. Acta Neuropathol Commun. 2018;6:22. https://doi.org/10.1186/s40478-018-0515-310.1186/s40478-018-0515-3.CrossRefPubMedPubMedCentral

110.

Butt AM, De La Rocha IC, Rivera A. Oligodendroglial Cells in Alzheimer's Disease. Adv Exp Med Biol. 2019;1175:325. https://doi.org/10.1007/978-981-13-9913-8_12.CrossRefPubMed

111.

Errea O, Rodriguez-Oroz MC. Oligodendrocytes, a New Player in the Etiology of Parkinson's Disease. Mov Disord. 2021;36:83. https://doi.org/10.1002/mds.28393.CrossRefPubMed

112.

Casella C, Lipp I, Rosser A, Jones DK, Metzler-Baddeley C. A Critical Review of White Matter Changes in Huntington's Disease. Mov Disord. 2020;35:1302. https://doi.org/10.1002/mds.28109.CrossRefPubMed

Title: Cell type-specific potential pathogenic genes and functional pathways in Alzheimer’s Disease
Authors: Xiao-Lan Wang
Lianjian Li
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Alzheimer's Disease
Alzheimer's Disease
Estrogens
Published in: BMC Neurology / Issue 1/2021
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-021-02407-1

2024 ASCO Annual Meeting

Springer Medicine

Cell type-specific potential pathogenic genes and functional pathways in Alzheimer’s Disease

Abstract

Background

Methods

Results

Conclusion

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Shifting of global aphasia to Wernicke’s aphasia in a patient with intact motor function: a case report

Understanding the relationship between the 32-item motor function measure and daily activities from an individual with spinal muscular atrophy and their caregivers’ perspective: a two-part study

Correction to: Rasch analysis of the Brain Injury Screening Tool (BIST) in mild traumatic brain injury

National registry for amyotrophic lateral sclerosis: a systematic review for structuring population registries of motor neuron diseases

Quality measurement of out-patient neuropsychological therapy after stroke in Germany: definition of indicators and retrospective pilot study

Study on the pathogenesis of Holmes tremor by multimodal 3D medical imaging: case reports of three patients